MedTrace Logo

Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease

NCT01009255 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 196

Last updated 2017-04-13

No results posted yet for this study

Summary

This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with mild to moderate Alzheimer's disease

Conditions

Interventions

DRUG

GSK239512

Histamine H3 Antagonist

DRUG

Placebo

Placebo to match GSK239512

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-02
Primary Completion
2010-11-10
Completion
2010-11-10

Countries

  • Bulgaria
  • Chile
  • Czechia
  • Germany
  • Russia
  • Slovakia
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01009255 on ClinicalTrials.gov